Requirement of dying cells and environmental adjuvants for the induction of autoimmunity

被引:57
作者
Bondanza, A
Zimmermann, VS
Dell'Antoni, G
Dal Cin, E
Balestrieri, G
Tincani, A
Amoura, Z
Piette, JC
Sabbadini, MG
Rovere-Querini, P
Manfredi, AA
机构
[1] San Raffaele Sci Inst, I-20132 Milan, Italy
[2] Univ Milan, Milan, Italy
[3] Spedali Civil Brescia, I-25125 Brescia, Italy
[4] CHU Pitie Salpetriere, Paris, France
来源
ARTHRITIS AND RHEUMATISM | 2004年 / 50卷 / 05期
关键词
D O I
10.1002/art.20187
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Cells commonly die without eliciting autoimmunity. However, dying cells are a potential initiating stimulus for systemic lupus erythematosus (SLE). Our goal was to verify whether immune adjuvants influence the autoimmunity induction that ensues following in vivo injection of dying cells. Methods. Mice were immunized with apoptotic thymocytes in the presence of artificial moieties, such as Freund's incomplete adjuvant (IFA), or natural adjuvants, such as dendritic cells (DCs). Renal involvement and the development of autoantibodies were monitored. Results. Apoptotic cells failed to induce clinical disease or to sustain production of autoantibodies in (NZB x NZW)F-1 mice. In contrast, autoimmunity developed in the presence of IFA or DCs. The characteristics of the adjuvant influenced the array of autoantibodies, the kinetics of their development, and the severity of the disease. DCs were required for induction of anti-beta(2)-glycoprotein I IgG. Adjuvants alone did not elicit disease. Conclusion. A "two-hit" signal composed of antoantigens and adjuvants initiates systemic autoimmunity. Moreover, environmental signals at the site of clearance of dead cells shape the features and the severity of the autoimmune disease. Strategies aimed at preventing the accumulation of dying cells and at modulating endogenous adjuvants may be beneficial for the treatment of SLE.
引用
收藏
页码:1549 / 1560
页数:12
相关论文
共 78 条
  • [1] NUCLEOSOME-RESTRICTED ANTIBODIES ARE DETECTED BEFORE ANTI-DSDNA AND/OR ANTIHISTONE ANTIBODIES IN SERUM OF MRL-MP LPR/LPR AND +/+-MICE, AND ARE PRESENT IN KIDNEY ELUATES OF LUPUS MICE WITH PROTEINURIA
    AMOURA, Z
    CHABRE, H
    KOUTOUZOV, S
    LOTTON, C
    CABRESPINES, A
    BACH, JF
    JACOB, L
    [J]. ARTHRITIS AND RHEUMATISM, 1994, 37 (11): : 1684 - 1688
  • [2] The role of nucleosomes in lupus
    Amoura, Z
    Koutouzov, S
    Piette, JG
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2000, 12 (05) : 369 - 373
  • [3] Apoptosis in systemic lupus erythematosus - Clinical implications
    Andrade, F
    Casciola-Rosen, L
    Rosen, A
    [J]. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2000, 26 (02) : 215 - +
  • [4] Baumann I, 2002, ARTHRITIS RHEUM-US, V46, P191, DOI 10.1002/1529-0131(200201)46:1<191::AID-ART10027>3.0.CO
  • [5] 2-K
  • [6] Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses
    Beg, AA
    [J]. TRENDS IN IMMUNOLOGY, 2002, 23 (11) : 509 - 512
  • [7] Adjuvants of immunity: Harnessing innate immunity to promote adaptive immunity
    Bendelac, A
    Medzhitov, R
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (05) : F19 - F23
  • [8] Interferon and granulopoiesis signatures in systemic lupus erythematosus blood
    Bennett, L
    Palucka, AK
    Arce, E
    Cantrell, V
    Borvak, J
    Banchereau, J
    Pascual, V
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (06) : 711 - 723
  • [9] Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity
    Bickerstaff, MCM
    Botto, M
    Hutchinson, WL
    Herbert, J
    Tennent, GA
    Bybee, A
    Mitchell, DA
    Cook, HT
    Butler, PJG
    Walport, MJ
    Pepys, MB
    [J]. NATURE MEDICINE, 1999, 5 (06) : 694 - 697
  • [10] Serum amyloid P component binds to late apoptotic cells and mediates their uptake by monocyte-derived macrophages
    Bijl, M
    Horst, G
    Bijzet, J
    Bootsma, H
    Limburg, PC
    Kallenberg, CGM
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (01): : 248 - 254